Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of rare structural variant events in newly diagnosed multiple myeloma
    Meeting Abstract

    Chojnacka, M.; Diamond, B.; Ziccheddu, B.; Rustad, E.; Boyle, E.; Maclachlan, K. H.; Blaney, P.; Usmani, S.; Morgan, G. J.; Landgren, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Ziccheddu, B.; Maclachlan, K. H.; Poos, A. M.; Chojnacka, M.; Diamond, B.; Boyle, E. M.; Blaney, P.; Gagler, D.; Zhang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient reported outcomes from GRIFFIN
    Meeting Abstract

    Silbermann, R.; Laubach, J.; Kaufman, J. L.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health-related quality of life for frail transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone: Subgroup analysis of MAIA Trial
    Meeting Abstract

    Perrot, A.; Facon, T.; Plesner, T.; Usmani, S.; Kumar, S. K.; Bahlis, N. J.; Hulin, C.; Orlowski, R. Z.; Nahi, H.; Mollee, P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Variability in pattern of mutational signatures in multiple myeloma as a function of racial origin
    Meeting Abstract

    Blaney, P.; Boyle, E. M.; Maclachlan, K. H.; Williams, L. S.; Gagler, D.; Sudha, P.; Poos, A. M.; Wang, Y.; Ghamlouch, H.; Tenenbaum, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Correlative analyses from MajesTEC-1
    Meeting Abstract

    Cortes-Selva, D.; Casneuf, T.; Vishwamitra, D.; Stein, S.; Perova, T.; Skerget, S.; Ramos, E.; van Steenbergen, L.; De Maeyer, D.; Boominathan, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • CART cell +/- maintenance will replace auto-SCT in NDMM
    Meeting Abstract

    Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save